Posted on August 20th, 2010 by
When it was approved by the FDA in 2001, imatinib, or GLEEVEC, was billed as a wonder drug that could help patients with chronic myeloid leukemia (CML), a fatal disease, live. A new study by researchers at the University of New Mexico’s Cancer Center has borne that out. Imatinib stops the leukemia in its tracks. As a result, patients who would have died without imatinib are now surviving. In some cases, there is a nearly six-fold increase in survival rates. Link
Tags: In the News
You must be logged-in to the site to post a comment.